National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

What this Trial Is About

Researchers are studying patients co-infected with hepatitis B and Delta viruses to better understand their condition and how different management approaches affect the disease. This observational study collects both past and ongoing data, including biological samples, to explore the natural and treated history of hepatitis Delta infection. The study is being conducted by ANRS, Emerging Infectious Diseases, with the goal of improving knowledge about this co-infection. Participants will be monitored following usual medical recommendations based on their treatment status. Those never treated or treated only with peginterferon alpha 2a will have check-ups every six months. Patients treated with specific hepatitis Delta therapies will be followed according to treatment protocols and routine care after treatment ends. The study includes blood sampling for a biobank and additional samples for sub-studies involving certain patient groups. Self-administered questionnaires are also part of the participation requirements. During the study, participants will undergo regular assessments including blood tests, questionnaires on quality of life and substance use, and monitoring of liver function and viral levels. Researchers will track numerous outcomes such as virological responses, treatment adherence, adverse events, liver fibrosis, and progression towards liver complications. The study includes follow-up visits scheduled at specific weeks during and after treatment, continuing until December 2027. This comprehensive monitoring helps researchers gather detailed information on the disease and treatment effects over time.

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses